HCL-TECHNOLOGIES
18.2.2020 05:31:11 CET | Business Wire | Press release
Global technology company HCL Technologies (HCL), today announced a new large contract with New Zealand dairy co-operative Fonterra to modernise and manage the entire technology infrastructure Fonterra employees around the world use every day.
The multi-year partnership with HCL Technologies will consolidate Fonterra’s technology suppliers and bring together the Co-op’s IT infrastructure services under one umbrella. The technology edge services provided by HCL will enhance Fonterra’s employee experience, to navigate through their business operations.
This partnership will also extend HCL’s New Zealand presence to three offices within the country and will bring around 60 new jobs to the Waikato region, as the local support services for Fonterra employees will be based at its Hamilton Delivery centre.
The partnership will reinforce HCL’s focus in supporting the local New Zealand IT ecosystem by investing in local skills and partnering with regional companies and tertiary education groups to develop the local expertise to fill these roles over the coming years.
Michael Horton, Executive Vice President & Country Manager, Australia & New Zealand, HCL Technologies, says “We have been supporting Fonterra for over a decade by managing its IT application support and maintenance portfolio including SAP. We are delighted to expand our partnership with Fonterra to modernize and manage the entire technology infrastructure. This will enable us to further support both Fonterra’s business strategy as well as the agri-tech sector overall in the region.”
Piers Shore, Fonterra Chief Information Officer, says “Fonterra is pleased to be able to draw on HCL’s global scale and efficiency.
“Fonterra employees have said there is room for us to improve the tools and technologies we use on a daily basis at work and this partnership with HCL will allow us to make major improvements for our employees in terms of end-user experience and provide the digital foundation to our transformation initiatives.
“Additionally, this partnership will enable us to improve our cyber security framework and strengthen our critical IT foundation. Through our partnership with HCL, we are consolidating our external IT suppliers and through this we expect to make significant savings relative to our existing infrastructure IT spend over the next five years.”
For more information, visit www.hcltech.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200217005505/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SymphonyAI Launches Eight AI Applications Purpose-Built for Energy Asset Reliability and Operational Performance20.4.2026 07:09:00 CEST | Press release
Eight AI applications engineered for asset reliability, operational performance, and emissions obligations SymphonyAI, a global leader in Vertical AI platforms, today announced eight new industrial AI applications purpose-built for energy operators, marking the most targeted expansion of IRIS Foundry into the energy sector to date. Unlike generic asset management software, these applications are engineered around the specific failure modes, process dynamics, and regulatory obligations of energy and resources operations — compressor surge, heat exchanger fouling, pipeline integrity degradation, refinery unit yield loss, and the growing compliance burden of EU methane regulation and emissions reporting. By combining SymphonyAI’s deep industrial ontology with IRIS Foundry’s ability to unify IT, OT, and IoT data from historians, SCADA systems, inspection databases, and enterprise platforms into a single governed intelligence layer, the new suite delivers causal AI at the point where energy
Petronor and H2SITE Partner to Pioneer High-Purity Hydrogen Production in Refining Through Advanced Membrane Technology20.4.2026 07:00:00 CEST | Press release
H2SITE, a technology company specialised in advanced hydrogen production and separation solutions, has signed a strategic agreement with Petronor, a leading refinery and key industrial player in the energy sector with a clear commitment to achieving net-zero emissions, to deploy its high-efficiency hydrogen separation technology at Petronor’s refinery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419792308/en/ The partnership sets the stage for the joint development of a pioneering First-of-a-Kind (FOAK) unit, integrating H2SITE’s proprietary membrane technology into the Steam Methane Reforming (SMR) process in refineries to improve overall plant efficiency, enhance CO₂ capture opportunities, and ultimately strengthen operational performance and industrial competitiveness. Petronor’s engineering and operations teams are joining forces with H2SITE’s technical experts, leveraging decades of refinery expertise, industrial
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom